Nuveen Preferred & Income Stock (NYSE: JPI)

Nuveen Preferred & Income (NYSE:JPI) Stock, Quote.Headers.trade-ideas

Nuveen Preferred & Income

Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.

News

Intraday Update

Markets

Movers

Trading Ideas

ABCB

ABEV

ACAM

ACBI

ACCO

ACEL

ACER

ACIW

ACLS

ACRS

ACST

ADOM

AEHR

AGRO

AIMC

AINV

AIRT

ALEX

ALGN

ALGT

ALOT

AMAL

AMKR

AMOT

AMPH

AMRB

AMSC

AMWD

ANIK

ANIX

AOSL

APEN

APLE

APOG

APPN

APYX

AQUA

ARCC

ARCO

ARDC

ARDS

ARKR

AROW

ARPO

ASRV

ATKR

ATRS

AVAL

AVNW

AWSM

AXNX

AZUL

Stocks That Hit 52-Week Lows On Thursday

ACHC

ACRE

ADIL

ADNT

ADTN

ADUS

AFIN

AGCO

AGNC

AGYS

ALKS

ALLY

ALTM

ALYA

AMBC

AMCX

AMPY

ANAT

APLS

APTV

APTX

APWC

ARGO

ARNC

AROC

ASGN

ATAX

ATEN

ATNX

ATRA

Stocks That Hit 52-Week Lows On Wednesday

AAOI

AAON

AAWW

ABMD

ABTX

ACGL

ACNB

ACRX

ADES

ADMA

ADMS

ADPT

AERI

AFGC

AFMD

AFYA

AGLE

AIMT

AKCA

AKRX

AKTS

ALBO

ALDX

ALRM

ALRS

Nuveen Preferred Securities & Income Opportunities Fund Common Shares

Nuveen Preferred and Income Term Fund

J.P. Morgan Exchange-Traded Fund Trust JPMorgan International Bond Opportunities ETF

JPMorgan Income ETF

JPMorgan Diversified Return International Equity ETF

JPMORGAN INDIAN INVST TR by JP Morgan Indian Investment Trust Plc

The program aims to re-engage patients with the healthcare system, delivering essential care to underserved communities in Sacramento, San Diego, Riverside, Los Angeles, San Bernadino, and Orange County through a partnership with a top 10 national insurance provider.

DCGO

DocGo ExpandsProgram To Enhance Healthcare Access For California Medi-Cal Enrollees/Patients/Members

Stock Split

General

ARQQ

Arqit Quantum Has Determined To Effect A 25:1 Reverse Share Split, Effective September 25

Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) reported quarterly earnings of &pound;0.22 per share&nbsp;a 61.4 percent decrease over earnings of &pound;0.57 per share from the same period last year. The company reported quarterly sales of &pound;194.418 million which missed the analyst consensus estimate of &pound;195.668 million by 0.64 percent. This is a 2.44 percent increase over sales of &pound;189.791 million the same period last year

Earnings

DAVA

Endava Q4 2024 Adj. EPS £0.22 May Not Be Comparable To £22.62 Estimate, Sales £194.418M Miss £195.668M Estimate

Per the terms of the Proposed Acquisition, Psyence Biomed will issue to Psyence Group shares of its common stock valued at&nbsp;$1.1 million&nbsp;dollars, at a price of&nbsp;$0.55&nbsp;per share, in exchange for Psyence Group&#39;s&nbsp;11.13%&nbsp;stake in PsyLabs.

Psyence Biomedical Enters Agreement With Psyence Group For Acquisition Of 11.13% Stake In Privately-held PsyLabs For About $1.1M

Roth MKM analyst Matt Koranda downgrades Vista Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>) from Buy to Neutral and maintains the price target from $42 to $42.

Downgrades

Price Target

Analyst Ratings

VSTO

Roth MKM Downgrades Vista Outdoor to Neutral, Maintains Price Target to $42

Biotech

Health Care

BTAI

Bioxcel Therapeutics Announced Its Clinical Prioritization, While Deprioritizing Sales Efforts For Its Approved Drug Igalmi (Dexmedetomidine) Sublingual Film. The Company Plans To Maintain Igalmi In The Market Without Its Current Commercial Infrastructure

Roth MKM analyst Scott Fortune initiates coverage on Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy rating and announces Price Target of $50.

Initiation

Roth MKM Initiates Coverage On Turning Point Brands with Buy Rating, Announces Price Target of $50

Larimar Therapeutics, Inc. - Common Stock

LRMR

Larimar Therapeutics Announced That Data From Its Nomlabofusp Phase 1 Studies And Phase 2 Dose Exploration Study, Some Of Which Has Been Previously Disclosed, Will Be Presented At The Annual International Congress For Ataxia Research

HC Wainwright &amp; Co. analyst Robert Burns upgrades Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) from Neutral to Buy and announces $5 price target.

Upgrades

PRLD

HC Wainwright & Co. Upgrades Prelude Therapeutics to Buy, Announces $5 Price Target

B. Riley Securities analyst Madison El-Saadi initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announces Price Target of $11.

B. Riley Securities Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $11

Commodities

Legal

TUSK

Cobra Acquisitions, A Subsidiary Of Mammoth Energy Services, Announced That The Previously Disclosed Settlement Agreement With The Puerto Rico Electric Power Authority Was Approved By The Title III Court, PREPA Required To Pay Cobra $150M Within Ten Business Days

<ul>
<li>One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers.&nbsp;</li>
<li>Another program aims to unravel new mechanisms of action that will allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure.&nbsp;</li>
<li>The Company plans on releasing new data from in-vitro and ex-vivo studies in these programs during the fourth quarter of 2024.</li>
</ul>

GLMD

Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years

B. Riley Securities initiates coverage on Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) with a Buy rating and announces Price Target of $33.

CNTA

B. Riley Securities Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $33

COEP

Coeptis Therapeutics Receives Notification Letter From Nasdaq Hearings Panel Granting Its Request For Continued Listing Through January 15, 2025

SYTA

Siyata Mobile Announced That Its SD7 Handsets And VK7 Vehicle Kits Were Purchased And Deployed By A New Customer, Trans-west Security Systems

Raymond James analyst Stephen Laws upgrades Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) from Market Perform to Outperform and announces $34 price target.

SAFE

Raymond James Upgrades Safehold to Outperform, Announces $34 Price Target

SpaceX CEO Elon Musk said on Thursday that the rocket manufacturing company intends to <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights">offer a trip to Mars</a> to anyone who volunteers in the future but warned that the journey might be uncomfortable.
What Happened: &#8220;In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go&#8230;&#8221; Musk wrote on social media platform X in response to former European Union Commissioner Thierry Breton with whom he has a history of sparring now and then.
However, the journey to Mars, Musk warned, will be like a &#8220;long sea voyage.&#8221;
&#8220;&#8230;.it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure!&#8221; Musk said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go, bearing in mind that it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure! Becoming multiplanetary ensures the long-term survival of life.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1836705091446853687?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk aims to take humans to Mars with SpaceX&#8217;s Starship launch vehicle in an attempt to &#8220;make life multi-planetary.&#8221; Musk has previously even envisioned a self-sustaining city on Mars called Terminus.
Why It Matters: Earlier this month, Musk said the first Starships will <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights" target="_blank" rel="noreferrer noopener">head to Mars in two years</a> once the next Earth-Mars transfer window opens.
The first launches to Mars in 2026, Musk then said, will not have a crew onboard and will be aimed at testing the flight's ability to land intact on Mars.
"If those landings go well, then the first crewed flights to Mars will be in 4 years," Musk wrote, pegging the first crewed Starship flights to the neighboring planet for 2028. A self-sustaining city, he said, should be ready in about 20 years. 
Starship, however, is still under development and undergoing test flights. It was last launched in June and the company is <a href="https://www.benzinga.com/news/24/09/40932353/spacex-continues-to-prepare-for-future-starship-flights-despite-delays-in-faa-launch-clearance-elon">now awaiting the green light </a>from the Federal Aviation Administration for its fifth flight test. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40934031/teamsters-opts-to-not-endorse-either-harris-or-trump-for-upcoming-presidential-elections-citing-fail">Teamsters Opts To Not Endorse Either Harris Or Trump For Upcoming Presidential Elections, Citing Failure To Secure Pledges Of Non-Interference In Union Campaigns</a></li>
</ul>
Image generated using Midjourney and official SpaceX photos on Flickr

SPACE

Tech

SpaceX CEO Elon Musk Says Anyone Can Go To Mars With SpaceX But Journey Would Be Like A 'Long Sea Voyage In Centuries Past'

HC Wainwright &amp; Co. analyst Arthur He reiterates Satellos Bioscience (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MSCL#TSX">MSCL</a>) with a Buy and maintains C$1.2 price target.

Reiteration

TSX:MSCL

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains C$1.2 Price Target

ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.&nbsp;

ACET

Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases

Offerings

Murphy Oil Intends To Offer $600M Of Senior Notes Due 2032

Current Alpha Opportunities In The CEF Space

Nuveen Preferred & Income Term Fund declares $0.098 dividend

Opportunities In Income Securities That Have Lagged The Rally

CEF Weekly Review: Neuberger Berman Doesn't Want To Be Left Out

HIE: Anticipated Termination Nearing

Nuveen Preferred & Income Term Fund raises dividend by 69.4% to $0.1660

JPI: Now A Perpetual CEF, Implications For Shareholders

CEF Weekly Review: Not Everything Is An Arbitrage

CEF Weekly Review: Reverse Splits Are Never A Good Sign

BCSF

GLAD

OBDC

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Nuveen Preferred & Income

Nuveen Preferred & Income (JPI) Forecast

Nuveen Preferred & Income (NYSE:JPI) Stock, Quote.Headers.trade-ideas